Oregon Attorney General Dan Rayfield filed a $900 million lawsuit against the nation's largest insulin manufacturers, ...

The biotech is developing drugs that target the biology of aging to treat obesity, cardiovascular disease, and more ...

Oregon is joining cities, unions, and states across the country that have filed lawsuits alleging pharmacy benefit mangers ...

Pharma stocks are back in focus as obesity drugs, HIV prevention and biotech deal activity shape the outlook heading into ...

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.3% in the morning session after the ...

Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...

Eli Lilly shares surged over 4.5% on analyst upgrades, acquisition rumors involving Ventyx Biosciences, and a new $1.3 ...

Eli Lilly is in advanced talks to acquire Ventyx Biosciences, which is developing pills for autoimmune conditions, for more ...

By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...

According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...

Indian pharmaceutical market (IPM) has registered a growth of 8.1 percent to touch ₹2,40,672 crore in 2025 and is likely to ...